Printer Friendly

Clinical usefulness of IgG food allergy testing.

Immunoglobulin G (IgG) food allergy testing has made vast advancements since 2003, when the American Academy of Allergy, Asthma, and Immunology published a statement that "Measurement of specific IgG antibodies to foods is also unproven as a diagnostic tool." (1) Most of the IgG food allergy throughout the world is done using the same immunochemical technique. First, soluble food proteins in solution are reacted to a solid phase that chemically binds to a variety of proteins. The use of plastic microtiter trays with one to several hundred wells has become the most common material used as the solid phase. Then these trays are washed, dried, and stored for later use. A sample of diluted serum is then added to each of the wells. Antibodies of all types in the diluted serum bind to the specific food molecules that are attached to the plastic wells of the tray. Next, the plates are washed to remove any nonspecific antibodies in the diluted serum. At this time, food antibodies from all of the five major immunoglobulin classes called G, A, M, E, and D may be attached to the food antigens on the plate. The next step confers specificity on the assay. Antisera from sheep, goats, rabbits, or other animals that specifically bind only to IgG (and not to IgA, IgM, IgE, or IgD) are added to microtiter wells. This antibody to IgG has previously been modified by the attachment of an enzyme that can be measured conveniently. The amount of enzyme bound to food antigen IgG complexes on the plate is directly related to how much IgG antibody is attached to a given food. The overall technique is termed enzyme-linked immunosorbent assay (ELISA). If lgG4 is measured, an antiserum specific for lgG4 only must be used for the final step.

Of particular interest was the group of patients with chronic, disabling symptoms, unresponsive to other intensive treatments. Whereas 70% obtained 75% or more improvement, 20% of these patients obtained 100% relief.

The clinical usefulness of IgG testing in an array of illnesses is illustrated in an early article published by an otolaryngologist who reported that the majority of his patients had substantial health improvements after an elimination of foods positive by IgG food allergy tests. (2) The overall results demonstrated a 71% success rate for all symptoms achieving at least a 75% improvement level. Of particular interest was the group of patients with chronic, disabling symptoms, unresponsive to other intensive treatments. Whereas 70% obtained 75% or more improvement, 20% of these patients obtained 100% relief. Symptoms that most commonly improved 75% to 100% on the elimination diets included asthma, coughing, ringing in the ears, chronic fatigue, all types of headaches, gas, bloating, diarrhea, skin rash and itching, and nasal congestion. The most common IgG food allergies were cow's milk, garlic, mustard, egg yolk, tea, and chocolate.

The usefulness of IgG food allergy to design customized elimination diets has now been documented in scientific studies. Irritable bowel syndrome (IBS) is a common, costly, and potentially disabling gastrointestinal (Gl) disorder characterized by abdominal pain/ discomfort with altered bowel habits (e.g., diarrhea, constipation). The major symptoms of IBS are abnormality of bowel movement, reduction in bowel sensitivity thresholds, and psychological abnormality. (1-3) Many IBS patients have psychological symptoms including depression, anxiety, tension, insomnia, frustration, hypochondria, and psychosocial factors. (3) Atkinson et al. evaluated a total of 150 outpatients with IBS who were randomized to receive, for 3 months, either a diet excluding all foods to which they had raised IgG antibodies (ELISA test) or a sham diet excluding the same number of foods but not those to which they had antibodies. (4) Patients on the diet dictated by IgG testing had significantly fewer symptoms than those on the sham diet after 120 days on the diets. Patients who adhered closely to the diet had a marked improvement in symptoms, while those with moderate or low adherence to the IgG test-dictated diets had poorer response. Similar results were also obtained by Drisko et al. (5) They used both elimination diet and probiotic treatment in an open label study of 20 patients with irritable bowel syndrome diagnosed at a medical school gastroenterology department. The most frequent positive serologic IgG antigen-antibody complexes found on the food IgG tests were: baker's yeast, 1 7 out of 20 (85%); onion mix, 13 out of 20 (65%); pork, 12 out of 20 (60%); peanut, 12 out of 20 (60%); corn, 11 out of 20 (55%); wheat, 10 out of 20 (50%); soybean, 10 (50%); carrot, 9 out of 20 (45%); cheddar cheese, 8 out of 20 (40%); egg white, 8 out of 20 (40%). Only 5 out of 20 reacted by IgG antibody production to dairy; however, the majority of patients reported eliminating dairy prior to trial enrollment, presumably clearing antigen-antibody complexes prior to testing. Significant improvements were seen in stool frequency, pain, and IBS quality of life scores. Imbalances of beneficial flora and dysbiotic flora were identified in 100% of subjects by comprehensive stool analysis. There was a trend to improvement of beneficial flora after treatment but no change in dysbiotic flora. The 1-year follow up demonstrated significant continued adherence to the food rotation diet, minimal symptomatic problems with IBS, and perception of control over IBS. The continued use of probiotics was considered less helpful.

IgG food allergy testing was also proved effective in the gastrointestinal disorder Crohn's disease. Bentz et al. found that an elimination diet dictated by IgG food allergy testing resulted in a marked reduction of stool frequency in a double-blind crossover study in which the IgG-dictated diet was compared with a sham diet in 40 patients with Crohn's disease. (6) IgG food allergies were significantly elevated compared with normal controls. Cheese and baker's yeast (Saccharomyces cerevisiae) allergies were extremely common, with rates of 83% and 84% respectively. Main et al., focusing on the baker's yeast allergy, also found extremely high prevalence of IgG allergy in patients with Crohn's disease. (7) Titers of both IgG and IgA to 5. cerevisiae in the patients with Crohn's disease were significantly higher than those in the controls. In contrast, antibody titers in the patients with ulcerative colitis were not significantly different from those in the controls. Among the patients with Crohn's disease there was no significant difference in antibody titers between patients with disease of the small or large bowel. Since IgG antibodies to 5. cerevisiae cross-react with Candida albicans, Candida species colonization might be a trigger for the development of Crohn's disease. (8)

IgG food allergy to wheat, gluten, gliadin, rye, and barley are prevalent in the gastrointestinal disorder celiac disease. Virtually all patients with celiac disease have elevated IgG antibodies to gliadin if they currently have wheat or related grains in their diet. Celiac disease is confirmed by the presence of flattened mucosa with a lack of villi when a biopsy sample of the small intestine is examined microscopically. Another confirmation test with equal sensitivity is a blood test for IgA transglutaminase antibodies. The antibody confirmation test is equal in accuracy to the biopsy test with the exception that individuals with IgA deficiency may have false negative results. However, I would estimate that only 1% of people with elevated IgG antibodies to gliadin and other grains related to wheat have celiac disease. If the result is negative for the confirmation tests for celiac disease, many patients are frequently erroneously advised that they have no problem with wheat. Hadjivassiliou et al. argued that it is a significant clinical error to classify wheat allergy through the filter of celiac disease and argue that celiac disease is a subtype of wheat sensitivity. (9) Many of their patients with wheat allergy but celiac-disease negative had remission of severe neurological illnesses when they adopted a glutenfree diet and expressed that in these patients the gluten molecule causes an autoimmune reaction in the brain rather than in the intestinal tract, likely against the Purkinje cells that are predominant in the cerebellum.

A wide range of additional studies has proved the clinical value of IgG antibodies in autism, bipolar depression, schizophrenia, migraine headaches, asthma, and obesity. (10-15)

Total IgG versus lgG4 Food Allergy

IgG is classified into several subclasses termed 1, 2, 3, and 4. IgGs are composed of two heavy chainlight chain pairs (half-molecules), which are connected via inter-heavy chain disulfide bonds situated in the hinge region (Figure 1). lgG4 antibodies usually represent less than 6% of the total IgG antibodies. lgG4 antibodies differ functionally from other IgG subclasses in their lack of inflammatory activity, which includes a poor ability to induce complement and immune cell activation because of low affinity for C1q (the q fragment of the first component of complement). Consequently, lgG4 has become the preferred subclass for immunotherapy, in which lgG4 antibodies to antigens are increased to reduce severe antigen reactions mediated by IgE. If antigens preferentially react with lgG4 antibodies, the antigens cannot react with IgE antibodies that might cause anaphylaxis or other severe reactions. Thus, lgG4 antibodies are often termed blocking antibodies. Another property of blood-derived lgG4 is its inability to cross-link identical antigens, which is referred to as functional monovalency. lgG4 antibodies are dynamic molecules that exchange half of the antibody molecule specific for one antigen with a heavy-light chain pair from another molecule specific for a different antigen, resulting in bispecific antibodies that cannot form large cross-linked antibodies that bind complement and thus cause subsequent inflammation. (16) In specific immunotherapy with allergen in allergic rhinitis, for example, increases in allergen-specific lgG4 levels indeed correlate with improved clinical responses. lgG4 antibodies block not only IgE-mediated food allergies but also the reactions of food antigens with other IgG subclasses, reducing inflammatory reactions caused by the other IgG subclasses of antibodies to food antigens.

In IgG-mediated food allergy testing, the goal is to identify foods that can cause inflammation and thus trigger a large number of adverse reactions. IgG 1, lgG2, and lgG3 can all cause inflammation because these antibodies do not exchange heavy and light chains with other antibodies to form bispecific antibodies. Thus, IgG 1, lgG2, and lgG3 antibodies to food antigens can and do form large immune complexes or lattices that fix complement and increase inflammation. The presence of lgG4 antibodies to food antigens indicates the presence of antibodies to foods that will not usually cause inflammation even though high amounts of these antibodies do indicate the presence of immune reactions against food antigens. Testing only for lgG4 antibodies in foods limits the ability of the clinician to determine those foods that are causing significant clinical reactions that are affecting their patients. The importance of measuring other subtypes of IgG antibodies is

highlighted in an article by Kemeny et al. (17) They found that IgG 1 antibodies to gluten were elevated in all 20 patients with celiac disease but none of the patients had elevated lgG4 antibodies to gluten.


(1.) Statement of the AAAAI Work Group Report: Current approach to the diagnosis and management of adverse reactions to foods [Web page], October 2003. http:// Accessed October 27, 2013.

(2.) Dixon H. Treatment of delayed food allergy based on specific immunoglobulin G RAST testing relief. Otoloryngol Head Neck Surg. 2000;123:48-54.

(3.) Nagisa Sugaya N, Nomura S. Relationship between cognitive appraisals of symptoms and negative mood for subtypes of irritable bowel syndrome. BioPsychoSocial Medicine 2008;2:9-14.

(4.) Atkinson W et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004;53:1459-1464.

(5.) Drisko J, Bischoff B, Hall M, McCallum R. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. I Am Coll Nutr. 2006;25: 514-522.

(6.) Bentz S, et al. Clinical relevance of IgG antibodies against food antigens in Crohn's disease: a double-blind cross-over diet intervention study. Digestion. 2010;81:252-264.

(7.) Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ. 1988;297:1105-1106.

(8.) Schaffer T, Mueller S, Flogerzi B, Seibold-Schmid B, Schoepfer AM, Seibold F. Anti Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans. Inflamm Bowel Dis. 2007;13:1339-1346.

(9.) Hadjivassiliou M, Grunewald RA, Davies-Jones GAB. Gluten sensitivity as a neurological illness. Neurol Neurosurg Psychiatry. 2002;72:560-563.

(10.) Vladimir T et al. Higher plasma concentration of food-specific antibodies in persons with autistic disorder in comparison to their siblings. Focus Autism Other Dev Disabl. 2008;23:176-185.

(11.) Severance EG et al. Immune activation by casein dietary antigens in bipolar disorder. Bipolar Disord. 2010;12:834-842.

(12.) Severance EG et al. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res. 2010;118:240-247.

(13.) Huber A et al. Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. Int Arch Allergy Immunol. 1998;115:67-72.

(14.) Vance G et al. Ovalbumin specific immunoglobulin G and subclass responses through the first five years of life in relation to duration of sensitization and the development of asthma. Clin Exp Allergy. 2004;34:14521459.

(15.) Wilders-Truschnig M et al. IgG antibodies against food antigens are correlated with inflammation and intima media thickness in obese juveniles. Exp Clin Endocrinol Diabetes. 2008;116:241-245.

(16.) Van der Neut Kolfschoten M et al. Anti-inflammatory activity of human lgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317:1554-1555.

(17.) Kemeny DM et al. Sub-class of IgG in allergic disease. I. IgG sub-class antibodies in immediate and non-immediate food allergy. Clin Allergy. 1986;16:571-581.

William Shaw, PhD, is the director of the Great Plains Laboratory in Lenexa, Kansas, specializing in metabolic, toxic, and nutritional factors in a wide range of human diseases. He received a PhD in biochemistry, genetics, and human physiology from the Medical University of South Carolina. He is board certified in both clinical chemistry and toxicological chemistry by the American Board of Clinical Chemistry, one of a handful of individuals in the world to hold dual certifications. He has supervised large endocrinology, nutritional biochemistry, toxicology, and immunology departments in positions at the Centers for Disease Control (CDC) and SmithKIine, one of the world's largest clinical laboratories, in Atlanta, Georgia. Dr. Shaw worked in the Health and Nutrition Examination Survey at CDC, the most comprehensive nutritional survey of the population of the US. He was director of clinical chemistry, endocrinology, organic acid testing, and toxicology at Children's Mercy Hospital, the teaching hospital of the University of Missouri at Kansas City School of Medicine, where he was an associate professor in the pathology department. Dr. Shaw has supervised the testing of over a million samples of blood and urine involving the use of virtually every modern technology in the field of laboratory medicine. Dr. Shaw was honored to recently receive the highest award from the International Academy for Child Brain Development in 2012.
COPYRIGHT 2014 The Townsend Letter Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Shaw, William
Publication:Townsend Letter
Article Type:Report
Date:Jan 1, 2014
Previous Article:Celiac disease and gluten-associated conditions: using laboratory measures to clarify etiology and determine course of treatment.
Next Article:Predictive biomarkers in personalized laboratory diagnosis and evidence based best practices outcome monitoring.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters